TY - JOUR T1 - Valacyclovir Treatment in Epstein-Barr Virus Subset Chronic Fatigue Syndrome: Thirty-six Months Follow-up JF - In Vivo JO - In Vivo SP - 707 LP - 713 VL - 21 IS - 5 AU - A. MARTIN LERNER AU - SAFEDIN H. BEQAJ AU - ROBERT G. DEETER AU - JAMES T. FITZGERALD Y1 - 2007/09/01 UR - http://iv.iiarjournals.org/content/21/5/707.abstract N2 - Background: We hypothesized that subset classification of Epstein-Barr virus (EBV) in chronic fatigue syndrome (CFS) is required. At first, a blinded-random placebo-controlled trial of valacyclovir in EBV CFS subset was performed (Group 1), and this EBV subset was followed for thirty-six months (Group 2). Patients were given valacyclovir at 14.3 mg/kg every 6 hours. The validated Energy Index (EI) point score assessing physical functional capacity, Holter monitor, multigated (radionuclide) MUGA rest/stress ventriculographic examination, EBV serum IgM viral capsid antibodies (VCA), and EBV early antigen diffuse (EA) were followed. After six-months, Group 1 CFS patients receiving valacyclovir experienced an increased mean least square EI point score +1.12 units (122 kcal/day), while the placebo cohort increased +0.42 EI units (65 kcal/day). EI point scores at Group 2 increased progressively. Sinus tachycardias decreased and abnormal cardiac wall motion improved. Serum antibody titers to EBV VCA IgM decreased. Patients resumed normal activities. Copyright © 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -